Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $298.09 Average Target Price from Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned a consensus rating of “Moderate Buy” from the twenty-five analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $298.61.

A number of research analysts have recently commented on ALNY shares. TD Cowen raised their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Scotiabank raised their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $237.98 on Friday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The stock has a market capitalization of $30.69 billion, a PE ratio of -90.83 and a beta of 0.34. The stock’s 50 day moving average price is $248.88 and its 200-day moving average price is $259.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the firm posted $1.15 earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Buying and Selling

In other news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,122 shares of company stock valued at $2,540,455. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ALNY. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Washington Trust Advisors Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $42,000. Finally, True Wealth Design LLC boosted its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.